Pathos AI, a clinical-stage technology company, has acquired a majority stake in the Belgium-based DeuterOncology. The deal, centered on the promising cancer therapy DO-2, was systematically driven by Pathos's proprietary AI platform, Foundry. This acquisition is a landmark example of an AI platform sourcing and executing a clinical-stage oncology transaction.
A New Paradigm in Drug Discovery
Pathos's Foundry platform operates by continuously analyzing vast scientific and clinical datasets to identify high-potential, undervalued oncology assets. This data-centric model bypasses traditional industry reliance on relationships and reputation for deal sourcing. Foundry flagged DO-2 in late 2025 as a top candidate based on its objective merits.
"The traditional approach to finding clinical assets is built on relationships... Foundry is built on data," stated Iker Huerga, CEO of Pathos AI. He emphasized that the platform evaluates every asset purely on its mechanism, clinical signal, and probability of success. This unbiased analysis ensured that the best molecule, DO-2, was selected.
The entire process, from initial identification to the final investment decision, was completed in a fraction of the time required by conventional due diligence. Foundry's comprehensive evaluation of clinical merit and competitive positioning provided a swift recommendation. This efficiency showcases AI's potential to accelerate critical decision-making in biopharma.
The Promise of DO-2 for Cancer Patients
The acquired asset, DO-2, is a third-generation MET kinase inhibitor for patients with MET-altered cancers like Non-Small Cell Lung Cancer (NSCLC). It was designed to address the significant tolerability issues, such as severe peripheral edema, that limit current MET inhibitors. This focus on safety could provide a major advantage for patients.
Early clinical data has been exceptionally promising, with a Phase 1 study showing 100% tumor shrinkage in all evaluable NSCLC patients with a specific mutation. The drug also demonstrated a superior safety profile, with a peripheral edema rate of just 5% compared to 62-82% for competitors. These results highlight its potential as a best-in-class therapy.
DO-2's unique deuterated structure and binding kinetics enable potent antitumor activity without causing the chronic side effects of other drugs. Dr. Timothy Perera, CEO of DeuterOncology, praised Pathos's "rigorous, data-driven analysis" in recognizing the program's potential. The drug's patent exclusivity extends to December 2040, securing its long-term value.
Foundry's Role Beyond Acquisition
The Foundry platform's function extends well beyond identifying acquisition targets, as it is designed to develop drugs as well. The same AI system that pinpointed DO-2 will now be instrumental in guiding its ongoing clinical development program. This integrated approach ensures continuity from discovery through to late-stage trials.
"We are not interested in process automation. We are redesigning drug development from first principles," Huerga explained, underscoring the company's ambitious vision. The DO-2 transaction is one of four major portfolio decisions made through Foundry in the first quarter of 2026 alone. This activity proves the system is a core component of Pathos's strategy.
Pathos AI's acquisition of DeuterOncology represents a landmark achievement in applying artificial intelligence to pharmaceutical research and development. The transaction validates a faster, more objective model for identifying and advancing promising new medicines like DO-2. This data-first approach could significantly accelerate the delivery of safer and more effective cancer therapies to patients worldwide.